DONATE TODAY
To Increase Patient Access

Transforming Tubulin Therapy For Brain Diseases

LEARN MORE ABOUT REGLAGENE
ABOUT REGLAGENE
  • Novel Therapeutics Are Lacking for Brain Cancer and Brain Diseases
  • Reglagene's lead program is a novel, orally administered, well-tolerated, blood–brain barrier penetrant therapy for the treatment of brain cancers.
  • Reglagene's product pipeline also includes disease indications driven by brain inflammation.
  • Reglagene Is Developing Novel Therapies for Diseases with High Unmet Medical Need
  • Potent, Orally Available, Blood–Brain Barrier Penetrant Therapies Are Rapidly Moving through Preclinical Development
SAFETY FIRST
Current cancer therapies are highly toxic. Most therapies are given intravenously and cause many unwanted side effects. It is important to the Reglagene team to develop orally available, well-tolerated medicines for patients to use in the comfort of their own homes.
BLOOD–BRAIN BARRIER (BBB) PENETRANT
Only 2% of all marketable drugs can cross the BBB, a filter that prevents toxins and medicines from entering the brain. Reglagene’s brain cancer therapy crosses the BBB and has nearly the same concentration in peripheral blood as in the brain.
WELL-VALIDATED TARGET
Reglagene's first therapy attacks a highly validated cancer target, previously inaccessible in brain cancer owing to the BBB. Many therapies and drug-delivery systems have tried and failed to access this target in brain. Reglagene has found a way to make this possible.
MEDICINES FOR A GLOBAL MARKET 
Reglagene accesses the advantages of what are known as small-molecule medicines. Benefits of small molecule medicines include: oral administration, low manufacturing costs, and well-traveled development and regulatory pathways.

Reglagene Pipeline

Reglagene is Transforming Tubulin Therapies for brain Diseases by discovering and developing novel therapies

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
Our Case For Change
EBCI In The News
Patient Support Services
Patient Resource Center
VOLUNTEER WITH EBCI
GET IN TOUCH
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram